Quoin’s QRX003 Stuns in Netherton Syndrome Trial with Skin-Healing Breakthrough

April 2, 2025

DENVER, Colo., Apr 02, 2025 (247marketnews.com)- Quoin Pharmaceuticals (NASDAQ:QNRX) reported stunning results from its ongoing pediatric Netherton Syndrome (NS) study. Six weeks into whole-body treatment with QRX003, a topical lotion targeting this rare skin disorder, the first young patient’s skin is nearly healed; a visual stunner that’s holding strong with daily dosing. This could be a lifeline for kids battling a disease with no cure or approved fix.

Beyond the durable healing, the patient’s ditched a cocktail of meds—antibiotics, antivirals, antihistamines, glucocorticoids—once staples for her fragile skin. Her pruritus (itch) Almost gone, delivering zero nightly sleep disruptions; a first in her life, no sedatives needed. There were no adverse events after six weeks of QRX003 use.

Dr. Michael Myers, Quoin’s CEO, commented, “As we continue to monitor the progress of this first patient to receive whole body application with QRX003, we are very pleased to announce that after 6 weeks of dosing we are seeing continued positive improvement and the patient’s skin is almost completely healed now. The patient continues to remain off previously needed medications including antihistamines, antivirals, and glucocorticoids, and she has not needed any antibiotics in the 6 weeks since the initiation of dosing with QRX003. Very importantly also, with her pruritus almost completely eliminated, the patient is still experiencing zero nightly sleep disturbances without the need for any sedating medications. For a majority of Netherton Syndrome patients, the continuous presence of chronically debilitating pruritus is the worst symptom of this disease and it severely impacts their ability to sleep or to even sit still for any period of time. Often heavy sedation is required to allow patients to sleep and sit still, which in turn has a major negative impact on their quality of life. The almost complete healing of the skin and the elimination of this chronically debilitating pruritus provides strong clinical evidence that QRX003 is successfully tackling the root causes of this disease and not merely providing symptomatic relief. Furthermore, I am very pleased to report that no adverse events have been reported after six full weeks of whole-body application of QRX003. Based on these positive results, approval has been received to initiate whole body application of QRX003 to a second pediatric Netherton patient. Testing is expected to commence in just a few weeks and we look forward to providing updates on both patients progress as we continue with our plans to further expand this study to include additional pediatric subjects.”

Regulators just greenlit testing on a second pediatric patient, doubling down on this estimated $1 billion rare disease market.

Netherton Syndrome, a brutal hereditary glitch from a SPINK5 gene mutation, wreaks havoc: leaky skin, infections, allergies, and stunted growth. QRX003, Quoin’s brainchild, mimics the missing LEKTI protein with a serine protease inhibitor, sealing the skin barrier and taming chaos.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.